Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) EPS (Weighted Average and Diluted): 2017-2024

Historic EPS (Weighted Average and Diluted) for Coherus Oncology (CHRS) over the last 8 years, with Dec 2024 value amounting to $0.25.

  • Coherus Oncology's EPS (Weighted Average and Diluted) rose 7.32% to -$0.38 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.43, marking a year-over-year increase of 576.39%. This contributed to the annual value of $0.25 for FY2024, which is 109.88% up from last year.
  • Coherus Oncology's EPS (Weighted Average and Diluted) amounted to $0.25 in FY2024, which was up 109.88% from -$2.53 recorded in FY2023.
  • In the past 5 years, Coherus Oncology's EPS (Weighted Average and Diluted) registered a high of $1.62 during FY2020, and its lowest value of -$3.81 during FY2021.
  • In the last 3 years, Coherus Oncology's EPS (Weighted Average and Diluted) had a median value of -$2.53 in 2023 and averaged -$2.01.
  • As far as peak fluctuations go, Coherus Oncology's EPS (Weighted Average and Diluted) tumbled by 335.19% in 2021, and later surged by 109.88% in 2024.
  • Yearly analysis of 5 years shows Coherus Oncology's EPS (Weighted Average and Diluted) stood at $1.62 in 2020, then crashed by 335.19% to -$3.81 in 2021, then grew by 1.31% to -$3.76 in 2022, then soared by 32.71% to -$2.53 in 2023, then spiked by 109.88% to $0.25 in 2024.